{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:45:14Z","timestamp":1784205914775,"version":"3.55.0"},"reference-count":133,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Adoptive cell therapies (ACTs) include chimeric antigen receptors (CARs), bispecific T-cell engagers (BiTES), tumor-infiltrating lymphocytes, and T-cell receptor (TCR) gene-modified T-cells. ACTs have significantly improved patient outcomes associated with hematologic malignancies. Recent advances have demonstrated their potential in solid tumors with promising clinical trial results signaling that they represent paradigm shift in oncologic care. As these therapies become standard care in solid tumors, medical oncologists must become adept at recognizing and managing their unique toxicities including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). This review synthesizes the latest clinical data on ACTs in solid tumors, highlighting key findings, and toxicity profiles. In addition, the review provides an overview of early recognition and evidence-based management of CRS and ICANS. Equipping clinicians with the necessary knowledge to navigate toxicity management will be essential in optimizing patient outcomes as ACTs are increasingly adopted in solid tumor oncology.<\/jats:p>","DOI":"10.1093\/oncolo\/oyaf431","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:49:35Z","timestamp":1772023775000},"source":"Crossref","is-referenced-by-count":1,"title":["Ready or not, here they come: a practical guide to adoptive T-cell therapies for solid tumors for medical oncologists"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3204-0579","authenticated-orcid":false,"given":"Tuan","family":"Hoang","sequence":"first","affiliation":[{"name":"Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre , Toronto, ON M5G 2M9,","place":["Canada"]},{"name":"Division of Oncology, Scarborough Health Network , Toronto, ON M1P 2V5,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameena","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre , Toronto, ON M5G 2M9,","place":["Canada"]},{"name":"Leicester Cancer Research Centre, University of Leicester , Leicester LE1 7RH,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Sacher","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre , Toronto, ON M5G 2M9,","place":["Canada"]},{"name":"Department of Immunology, University of Toronto , Toronto, ON M5S 3K3,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"2026031114025265000_oyaf431-B1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med."},{"key":"2026031114025265000_oyaf431-B2","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med."},{"key":"2026031114025265000_oyaf431-B3","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"2026031114025265000_oyaf431-B4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark Res."},{"key":"2026031114025265000_oyaf431-B5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol."},{"key":"2026031114025265000_oyaf431-B6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","article-title":"Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains","volume":"11","author":"Lam","year":"2020","journal-title":"Nat Commun."},{"key":"2026031114025265000_oyaf431-B7","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1111\/cas.14169","article-title":"Improved survival of chimeric antigen receptor-engineered T (CAR -T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells","volume":"110","author":"Nakajima","year":"2019","journal-title":"Cancer Sci."},{"key":"2026031114025265000_oyaf431-B8","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026031114025265000_oyaf431-B9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/356607a0","article-title":"CD28-mediated signalling co-stimulates murine T cells and prevents induction of energy in T-cell clones","volume":"356","author":"Harding","year":"1992","journal-title":"Nature."},{"key":"2026031114025265000_oyaf431-B10","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia."},{"key":"2026031114025265000_oyaf431-B11","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin\u2019s lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol Ther."},{"key":"2026031114025265000_oyaf431-B12","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther."},{"key":"2026031114025265000_oyaf431-B13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med."},{"key":"2026031114025265000_oyaf431-B14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer."},{"key":"2026031114025265000_oyaf431-B15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat Rev Clin Oncol."},{"key":"2026031114025265000_oyaf431-B16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","article-title":"Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments","volume":"21","author":"Dagar","year":"2023","journal-title":"J Transl Med."},{"key":"2026031114025265000_oyaf431-B17","doi-asserted-by":"publisher","first-page":"102353","DOI":"10.1016\/j.xcrm.2025.102353","article-title":"CAR-T cells in solid tumors: challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep Med."},{"key":"2026031114025265000_oyaf431-B18","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity."},{"key":"2026031114025265000_oyaf431-B19","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","article-title":"Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat Commun."},{"key":"2026031114025265000_oyaf431-B20","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","article-title":"Cancer-associated fibroblasts: from basic science to anticancer therapy","volume":"55","author":"Yang","year":"2023","journal-title":"Exp Mol Med."},{"key":"2026031114025265000_oyaf431-B21","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer."},{"key":"2026031114025265000_oyaf431-B22","doi-asserted-by":"crossref","first-page":"e1700167","DOI":"10.1002\/pmic.201700167","article-title":"Cancer associated fibroblasts: the architects of stroma remodeling","volume":"18","author":"Santi","year":"2018","journal-title":"Proteomics."},{"key":"2026031114025265000_oyaf431-B23","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth\u00a0factor receptor 2 (HER2)\u2013specific chimeric antigen receptor\u2013modified T cells for the immunotherapy of HER2-Positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026031114025265000_oyaf431-B24","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-specific chimeric antigen receptor\u2013modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol."},{"key":"2026031114025265000_oyaf431-B25","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1007\/s00432-021-03613-7","article-title":"Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients","volume":"147","author":"Zhang","year":"2021","journal-title":"J Cancer Res Clin Oncol."},{"key":"2026031114025265000_oyaf431-B26","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med."},{"key":"2026031114025265000_oyaf431-B27","doi-asserted-by":"crossref","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci. Transl. Med"},{"key":"2026031114025265000_oyaf431-B28","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med."},{"key":"2026031114025265000_oyaf431-B29","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med."},{"key":"2026031114025265000_oyaf431-B30","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti\u2013PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"2026031114025265000_oyaf431-B31","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin Cancer Res."},{"key":"2026031114025265000_oyaf431-B32","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2019.37.15_suppl.2509","article-title":"Phase I trial of claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma","volume":"37","author":"Zhan","year":"2019","journal-title":"JCO."},{"key":"2026031114025265000_oyaf431-B33","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat Med."},{"key":"2026031114025265000_oyaf431-B34","doi-asserted-by":"crossref","first-page":"1846926","DOI":"10.1080\/2162402X.2020.1846926","article-title":"Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial","volume":"9","author":"Dai","year":"2020","journal-title":"Oncoimmunology."},{"key":"2026031114025265000_oyaf431-B35","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol Ther."},{"key":"2026031114025265000_oyaf431-B36","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1200\/JCO.23.02229","article-title":"STRIvE-02: a first-in-human phase I study of systemically administered B7-H3 chimeric antigen receptor T cells for patients with relapsed\/refractory solid tumors","volume":"42","author":"Pinto","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026031114025265000_oyaf431-B37","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N Engl J Med."},{"key":"2026031114025265000_oyaf431-B38","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol Ther."},{"key":"2026031114025265000_oyaf431-B39","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2013BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol."},{"key":"2026031114025265000_oyaf431-B40","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer."},{"key":"2026031114025265000_oyaf431-B41","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","article-title":"T cell activation","volume":"27","author":"Smith-Garvin","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"2026031114025265000_oyaf431-B42","doi-asserted-by":"crossref","first-page":"e0183390","DOI":"10.1371\/journal.pone.0183390","article-title":"Bispecific T cell engager (BiTE\u00ae) antibody constructs can mediate bystander tumor cell killing","volume":"12","author":"Ross","year":"2017","journal-title":"PLoS One."},{"key":"2026031114025265000_oyaf431-B43","doi-asserted-by":"crossref","first-page":"1190379","DOI":"10.3389\/fimmu.2023.1190379","article-title":"Cytokine release syndrome and cancer immunotherapies\u2014historical challenges and promising futures","volume":"14","author":"Shah","year":"2023","journal-title":"Front Immunol"},{"key":"2026031114025265000_oyaf431-B44","doi-asserted-by":"crossref","first-page":"28059","DOI":"10.18632\/oncotarget.8574","article-title":"Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and fc\u03b3 receptors","volume":"7","author":"Borlak","year":"2016","journal-title":"Oncotarget."},{"key":"2026031114025265000_oyaf431-B45","doi-asserted-by":"publisher","first-page":"e1450710","DOI":"10.1080\/2162402X.2018.1450710","article-title":"A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM\/CD3 T-cell engager (BiTE\u00ae) antibody construct, in patients with refractory solid tumors","volume":"7","author":"Kebenko","year":"2018","journal-title":"Oncoimmunology."},{"key":"2026031114025265000_oyaf431-B46","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med."},{"key":"2026031114025265000_oyaf431-B47","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N Engl J Med."},{"key":"2026031114025265000_oyaf431-B48","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med."},{"key":"2026031114025265000_oyaf431-B49","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med."},{"key":"2026031114025265000_oyaf431-B50","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.jtho.2024.09.059","article-title":"OA10.05 phase I trial of DLL3\/CD3 IgG-like T-cell engager BI 764532 in patients with DLL3-positive tumors: patients with LCNEC","volume":"19","author":"Wermke","year":"2024","journal-title":"J Thor Oncol"},{"key":"2026031114025265000_oyaf431-B51","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2019.37.15_suppl.5034","article-title":"Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting bispecific T cell engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC)","volume":"37","author":"Hummel","year":"2019","journal-title":"JCO."},{"key":"2026031114025265000_oyaf431-B52","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2217\/imt-2020-0256","article-title":"Pasotuxizumab, a bite\u00ae immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings","volume":"13","author":"Hummel","year":"2021","journal-title":"Immunotherapy."},{"key":"2026031114025265000_oyaf431-B53","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","article-title":"A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer","volume":"30","author":"Dorff","year":"2024","journal-title":"Clin Cancer Res."},{"key":"2026031114025265000_oyaf431-B54","doi-asserted-by":"crossref","first-page":"TPS5590","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS5590","article-title":"Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"38","author":"Tran","year":"2020","journal-title":"JCO."},{"key":"2026031114025265000_oyaf431-B55","doi-asserted-by":"crossref","first-page":"e16278","DOI":"10.1200\/JCO.2021.39.15_suppl.e16278","article-title":"Efficacy and safety of MUC1 targeted CIK cells for the treatment of advanced liver cancer","volume":"39","author":"Lu","year":"2021","journal-title":"JCO."},{"key":"2026031114025265000_oyaf431-B56","doi-asserted-by":"crossref","first-page":"e002194","DOI":"10.1136\/jitc-2020-002194","article-title":"Phase II clinical trial using anti-CD3 \u00d7 anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0\u20132+) metastatic breast cancer","volume":"9","author":"Lum","year":"2021","journal-title":"J Immunother Cancer."},{"key":"2026031114025265000_oyaf431-B57","doi-asserted-by":"crossref","first-page":"vi283","DOI":"10.1093\/neuonc\/noz219.1195","article-title":"ATIM-49 (LTBK-01). AMG 596, a novel anti-EGFRVIII bispecific T cell engager (Bite\u00ae) molecule for the treatment of glioblastoma (GBM): planned interim analysis in recurrent GBM (RGBM)","volume":"21","author":"Rosenthal","year":"2019","journal-title":"Neuro Oncol"},{"key":"2026031114025265000_oyaf431-B58","doi-asserted-by":"crossref","first-page":"CT111","DOI":"10.1158\/1538-7445.AM2021-CT111","article-title":"Abstract CT111: results of a phase 1 dose escalation study of ERY974, an anti-glypican 3 (GPC3)\/CD3 bispecific antibody, in patients with advanced solid tumors","volume":"81","author":"Safran","year":"2021","journal-title":"Cancer Res"},{"key":"2026031114025265000_oyaf431-B59","doi-asserted-by":"crossref","first-page":"100821","DOI":"10.1016\/j.esmoop.2023.100821","article-title":"41P phase I analysis of ubamatamab (MUC16xCD3 bispecific antibody) in patients with recurrent ovarian cancer","volume":"8","author":"Moore","year":"2023","journal-title":"ESMO Open."},{"key":"2026031114025265000_oyaf431-B60","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1038\/s41467-024-48479-8","article-title":"CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional phase 1 trials","volume":"15","author":"Segal","year":"2024","journal-title":"Nat Commun."},{"key":"2026031114025265000_oyaf431-B61","doi-asserted-by":"crossref","first-page":"TPS8611","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8611","article-title":"Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304)","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"JCO."},{"key":"2026031114025265000_oyaf431-B62","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1016\/j.jtho.2024.09.372","article-title":"P1.13A.02 tarlatamab plus durvalumab as first-line maintenance in extensive-stage small cell lung cancer: DeLLphi-305 phase 3 trial","volume":"19","author":"Perol","year":"2024","journal-title":"J Thor Oncol"},{"key":"2026031114025265000_oyaf431-B63","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.3389\/fimmu.2019.02250","article-title":"Engineered T cell therapy for cancer in the clinic","volume":"10","author":"Zhao","year":"2019","journal-title":"Front Immunol"},{"key":"2026031114025265000_oyaf431-B64","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1158\/2326-6066.CIR-22-0040","article-title":"Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor\u2013engineered T cells targeting common p53 neoantigens in human solid tumors","volume":"10","author":"Kim","year":"2022","journal-title":"Cancer Immunol Res."},{"key":"2026031114025265000_oyaf431-B65","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-cell receptor gene therapy in pancreatic cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N Engl J Med."},{"key":"2026031114025265000_oyaf431-B66","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","article-title":"Non-viral precision T cell receptor replacement for personalized cell therapy","volume":"615","author":"Foy","year":"2023","journal-title":"Nature."},{"key":"2026031114025265000_oyaf431-B67","doi-asserted-by":"crossref","first-page":"eabe2606","DOI":"10.1126\/scisignal.abe2606","article-title":"Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function","volume":"14","author":"Salter","year":"2021","journal-title":"Sci Signal"},{"key":"2026031114025265000_oyaf431-B68","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40164-024-00504-8","article-title":"Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy","volume":"13","author":"Shao","year":"2024","journal-title":"Exp Hematol Oncol."},{"key":"2026031114025265000_oyaf431-B69","doi-asserted-by":"crossref","first-page":"v481","DOI":"10.1093\/annonc\/mdz253.010","article-title":"Results of a phase I trial with MART-1 T cell receptor modified T cells in patients with metastatic melanoma","volume":"30","author":"Rohaan","year":"2019","journal-title":"Ann Oncol"},{"key":"2026031114025265000_oyaf431-B70","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1158\/1078-0432.CCR-23-1456","article-title":"Safety and efficacy of NY-ESO-1 antigen-specific T-cell receptor gene-transduced T lymphocytes in patients with synovial sarcoma: a phase I\/II clinical trial","volume":"29","author":"Kawai","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2026031114025265000_oyaf431-B71","doi-asserted-by":"crossref","first-page":"101133","DOI":"10.1016\/j.xcrm.2023.101133","article-title":"Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A\u221702:01 patients with advanced soft tissue sarcoma","volume":"4","author":"Pan","year":"2023","journal-title":"Cell Rep Med."},{"key":"2026031114025265000_oyaf431-B72","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1\u2013specific TCR\u2013engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat Med."},{"key":"2026031114025265000_oyaf431-B73","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","article-title":"Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Nat Med."},{"key":"2026031114025265000_oyaf431-B74","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/CJI.0000000000000348","article-title":"Re-examination of MAGE-A3 as a T-cell therapeutic target","volume":"44","author":"Martin","year":"2021","journal-title":"J Immunother."},{"key":"2026031114025265000_oyaf431-B75","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J Immunother."},{"key":"2026031114025265000_oyaf431-B76","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D\u2019Angelo","year":"2024","journal-title":"Lancet"},{"key":"2026031114025265000_oyaf431-B77","author":"U.S. Food and Drug Administration"},{"key":"2026031114025265000_oyaf431-B78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellimm.2011.12.004","article-title":"Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures","volume":"273","author":"Junker","year":"2012","journal-title":"Cell Immunol."},{"key":"2026031114025265000_oyaf431-B79","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med."},{"key":"2026031114025265000_oyaf431-B80","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"J Natl Cancer Inst."},{"key":"2026031114025265000_oyaf431-B81","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J Hematol Oncol."},{"key":"2026031114025265000_oyaf431-B82","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res."},{"key":"2026031114025265000_oyaf431-B83","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026031114025265000_oyaf431-B84","author":"U.S. Food and Drug Administration"},{"key":"2026031114025265000_oyaf431-B85","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol."},{"key":"2026031114025265000_oyaf431-B86","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood."},{"key":"2026031114025265000_oyaf431-B87","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"2026031114025265000_oyaf431-B88","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer."},{"key":"2026031114025265000_oyaf431-B89","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol."},{"key":"2026031114025265000_oyaf431-B90","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"2026031114025265000_oyaf431-B91","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood."},{"key":"2026031114025265000_oyaf431-B92","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.3390\/cancers13153912","article-title":"Treatment-related adverse events of chimeric antigen receptor T-cell (CAR T) in clinical trials: a systematic review and meta-analysis","volume":"13","author":"Lei","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2026031114025265000_oyaf431-B93","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"key":"2026031114025265000_oyaf431-B94","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med."},{"key":"2026031114025265000_oyaf431-B95","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2013assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"key":"2026031114025265000_oyaf431-B96","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"key":"2026031114025265000_oyaf431-B97","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med."},{"key":"2026031114025265000_oyaf431-B98","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"key":"2026031114025265000_oyaf431-B99","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.anai.2022.10.025","article-title":"Interleukin-6 and cytokine release syndrome","volume":"130","author":"Lee","year":"2023","journal-title":"Ann Allergy Asth Immunol"},{"key":"2026031114025265000_oyaf431-B100","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol."},{"key":"2026031114025265000_oyaf431-B101","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2147\/IJGM.S23920","article-title":"Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports","author":"Mahmud","year":"2011","journal-title":"IJGM"},{"key":"2026031114025265000_oyaf431-B102","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/rheumatology\/kex221","article-title":"Toxic drug-induced liver failure during therapy of rheumatoid arthritis with tocilizumab subcutaneously: a case report","volume":"56","author":"Anger","year":"2017","journal-title":"Rheumatology (Oxford)."},{"key":"2026031114025265000_oyaf431-B103","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/TCRM.S150524","article-title":"Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy","volume":"15","author":"Riegler","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"2026031114025265000_oyaf431-B104","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2018.09.024","article-title":"American society for blood and marrow transplantation pharmacy special interest group survey on chimeric antigen receptor T cell therapy administrative, logistic, and toxicity management practices in the United States","volume":"25","author":"Mahmoudjafari","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"2026031114025265000_oyaf431-B105","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant Cell Ther."},{"key":"2026031114025265000_oyaf431-B106","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jcmm.16176","article-title":"Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy","volume":"25","author":"Pan","year":"2021","journal-title":"J Cell Mol Med."},{"key":"2026031114025265000_oyaf431-B107","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1158\/1078-0432.CCR-20-1739","article-title":"Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy","volume":"26","author":"Huarte","year":"2020","journal-title":"Clin Cancer Res."},{"key":"2026031114025265000_oyaf431-B108","doi-asserted-by":"crossref","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"key":"2026031114025265000_oyaf431-B109","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2643-3230.BCD-21-0203","article-title":"Potential role of IFN\u03b3 inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy","volume":"3","author":"McNerney","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"2026031114025265000_oyaf431-B110","doi-asserted-by":"crossref","first-page":"e001114","DOI":"10.1136\/jitc-2020-001114","article-title":"Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2","volume":"8","author":"Wang","year":"2020","journal-title":"J Immunother Cancer."},{"key":"2026031114025265000_oyaf431-B111","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1182\/blood.2022017414","article-title":"How I treat refractory CRS and ICANS following CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood Blood"},{"key":"2026031114025265000_oyaf431-B112","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.1182\/blood.V128.22.5702.5702","article-title":"Posterior reversible encephalopathy syndrome (PRES) after infusion of anti-BCMA CAR T cells (CART-BCMA) for multiple myeloma: successful treatment with cyclophosphamide","volume":"128","author":"Garfall","year":"2016","journal-title":"Blood"},{"key":"2026031114025265000_oyaf431-B113","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2147\/DDDT.S195294","article-title":"Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy","volume":"13","author":"Cohen","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"2026031114025265000_oyaf431-B114","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/bloodadvances.2020001792","article-title":"BiTEs better than CAR T cells","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv."},{"key":"2026031114025265000_oyaf431-B115","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia","volume":"2016","author":"Frey","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2026031114025265000_oyaf431-B116","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med."},{"key":"2026031114025265000_oyaf431-B117","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/bloodadvances.2022006983","article-title":"Anakinra utilization in refractory pediatric CAR T-cell associated toxicities","volume":"6","author":"Diorio","year":"2022","journal-title":"Blood Adv."},{"key":"2026031114025265000_oyaf431-B118","doi-asserted-by":"crossref","first-page":"e003847","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J Immunother Cancer."},{"key":"2026031114025265000_oyaf431-B119","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood."},{"key":"2026031114025265000_oyaf431-B120","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood-2019-126081","article-title":"Earlier steroid use with axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory large B cell lymphoma","volume":"134","author":"Topp","year":"2019","journal-title":"Blood"},{"key":"2026031114025265000_oyaf431-B121","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-020-0280-y","article-title":"Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia","volume":"10","author":"Liu","year":"2020","journal-title":"Blood Cancer J"},{"key":"2026031114025265000_oyaf431-B122","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/biom13020382","article-title":"Early use of corticosteroids following CAR T-cell therapy correlates with reduced risk of high-grade CRS without negative impact on neurotoxicity or treatment outcome","volume":"13","author":"Lakomy","year":"2023","journal-title":"Biomolecules."},{"key":"2026031114025265000_oyaf431-B123","doi-asserted-by":"crossref","first-page":"745320","DOI":"10.3389\/fimmu.2021.745320","article-title":"Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front Immunol"},{"key":"2026031114025265000_oyaf431-B124","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"2026031114025265000_oyaf431-B125","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood.V126.23.3769.3769","article-title":"Efficient trafficking of chimeric antigen receptor (CAR)-modified T cells to CSF and induction of durable CNS remissions in children with CNS\/combined relapsed\/refractory ALL","volume":"126","author":"Rheingold","year":"2015","journal-title":"Blood"},{"key":"2026031114025265000_oyaf431-B126","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ana.25315","article-title":"Neurotoxicity after CTL019 in a pediatric and young adult cohort","volume":"84","author":"Gofshteyn","year":"2018","journal-title":"Ann Neurol."},{"key":"2026031114025265000_oyaf431-B127","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"2026031114025265000_oyaf431-B128","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood."},{"key":"2026031114025265000_oyaf431-B129","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/PPO.0000000000000377","article-title":"Management of T-cell engaging immunotherapy complications","volume":"25","author":"Varadarajan","year":"2019","journal-title":"Cancer J."},{"key":"2026031114025265000_oyaf431-B130","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/B978-0-323-66181-2.00007-X","volume-title":"Chimeric Antigen Receptor T-Cell Therapies for Cancer","author":"Gust","year":"2020"},{"key":"2026031114025265000_oyaf431-B131","doi-asserted-by":"publisher","first-page":"100737","DOI":"10.1016\/j.iotech.2024.100737","article-title":"Solid tumour cellular therapy\u2013principles of toxicity management","volume":"25","author":"Julve","year":"2025","journal-title":"Immunooncol Technol"},{"key":"2026031114025265000_oyaf431-B132","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol."},{"key":"2026031114025265000_oyaf431-B133","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf431\/67112113\/oyaf431.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyaf431\/67112113\/oyaf431.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyaf431\/67112113\/oyaf431.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T18:04:55Z","timestamp":1773252295000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf431\/8497596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":133,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf431","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,2,25]]},"article-number":"oyaf431"}}